Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CADM1 is a TWIST1-regulated suppressor of invasion and survival.
Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH 3rd, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. Hartsough EJ, et al. Among authors: chervoneva i. Cell Death Dis. 2019 Mar 25;10(4):281. doi: 10.1038/s41419-019-1515-3. Cell Death Dis. 2019. PMID: 30911007 Free PMC article.
In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Teh JLF, et al. Among authors: chervoneva i. Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Cancer Discov. 2018. PMID: 29496664 Free PMC article.
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. Capparelli C, et al. Among authors: chervoneva i. Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16. Cancer Res. 2018. PMID: 30115691 Free PMC article.
Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Teh JLF, et al. Among authors: chervoneva i. Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. Cancer Discov. 2018. PMID: 30510016 No abstract available.
143 results